BCR::ABL1 enhances cell survival in CML by activating several signaling pathways, including mitogen-activated protein kinase (MAPK), AKT, and STAT5, which were downregulated with the TKI treatment [32–34]. This evidence concerns the gene WNK2 and chronic myelogenous leukemia, BCR-ABL1 positive.